The Role of Hypoxia in Ischemic Chronic Kidney Disease.
Textor SC, Lerman LO.
Semin Nephrol. 2019 Nov;39(6):589-598. doi: 10.1016/j.semnephrol.2019.10.008.
Nanomedicine in kidney disease.
Bishop B, Sharma S, Scott EA.
Curr Opin Nephrol Hypertens. 2023 Jul 1;32(4):366-376. doi: 10.1097/MNH.0000000000000897. Epub 2023 May 11.
[Ischemic kidney disease].
Mustonen J, Wirta O.
Duodecim. 2006;122(2):208-14.
Concise review: mesenchymal stem cell treatment for ischemic kidney disease.
Zhu XY, Lerman A, Lerman LO.
Stem Cells. 2013 Sep;31(9):1731-6. doi: 10.1002/stem.1449.
Chronic kidney disease exacerbates ischemic limb myopathy in mice via altered mitochondrial energetics.
Berru FN, Gray SE, Thome T, Kumar RA, Salyers ZR, Coleman M, Dennis Le, O'Malley K, Ferreira LF, Berceli SA, Scali ST, Ryan TE.
Sci Rep. 2019 Oct 29;9(1):15547. doi: 10.1038/s41598-019-52107-7.
Atherosclerotic ischemic renal disease.
Greco BA, Breyer JA.
Am J Kidney Dis. 1997 Feb;29(2):167-87. doi: 10.1016/s0272-6386(97)90027-5.
Pseudogene GSTM3P1 derived long non-coding RNA promotes ischemic acute kidney injury by target directed microRNA degradation of kidney-protective mir-668.
Wei Q, Huang J, Livingston MJ, Wang S, Dong G, Xu H, Zhou J, Dong Z.
Kidney Int. 2024 Oct;106(4):640-657. doi: 10.1016/j.kint.2024.06.027. Epub 2024 Jul 27.
Role of T cells in ischemic acute kidney injury and repair.
Lee K, Jang HR.
Korean J Intern Med. 2022 May;37(3):534-550. doi: 10.3904/kjim.2021.526. Epub 2022 Apr 28.
Pre-uremic calciphylaxis.
Nayer A, Virmani S, Gonzalez-Suarez M, Goez-Gutierrez E, Rosenberg AE, Salman LH, Asif A.
Iran J Kidney Dis. 2014 May;8(3):252-6.
Emergent players in renovascular disease.
Barsom SH, Glasstetter LM, Siddiqi S, Rajagopalan KS, Eirin A, Lerman LO.
Clin Sci (Lond). 2022 Feb 11;136(3):239-256. doi: 10.1042/CS20210509.
